News | August 05, 2021
Dr. Reddy's Laboratories signs asset purchase agreement with BioDelivery Sciences
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
The company has been consistently reducing debt
Deal for 100 million doses with additional 100 million through 2023
Aditya Puri former MD of HDFC bank joins Solara board as chairman
The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
